Tirzepatide

Obesity is an important health issue for patients with chronic kidney disease, speeding its progression, contributing to disability and limiting access to organ transplantation. Up to now, nephrologists typically do not manage obesity.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.

In this video, Jamy D. Ard, MD, FTOS, discusses treatment options, lifestyle interventions and strategies for patients with obesity.

The FDA has confirmed there is no longer a shortage of tirzepatide and has set dates for companies to cease distribution of compounded forms of the agent, according to an announcement from the agency.

A post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials found that early responders to tirzepatide, or those who lost at least 5% of body weight by 8 weeks, had greater weight loss and cardiometabolic benefits vs. non-early responders.

SAN ANTONIO — Tirzepatide confers significant weight loss and cardiometabolic benefits for patients with diabetes and overweight or obesity, especially for those who lose more weight earlier during treatment, a speaker reported.

Eli Lilly announced top-line results of the SURMOUNT-5 trial in which patients with overweight or obesity assigned tirzepatide lost more weight than those assigned semaglutide.

CHICAGO — In adults with HF with preserved ejection fraction and obesity, treatment with tirzepatide cut risk for CV death or worsening HF by 38% compared with placebo, with a parallel improvement in health status and exercise tolerance.

A pilot study revealed that patients treated with the antipsychotic olanzapine plus an intestinal microsomal triglyceride transfer protein inhibitor had an 82% reduction in postprandial triglycerides vs. those treated with olanzapine alone.

PHILADELPHIA — Tirzepatide 15 mg produced similar weight loss results as bariatric surgery among patients with obesity but had a favorable safety profile, according to a presenter at the ACG Annual Scientific Meeting.